Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer.
Holt S, Verrill M, Pettit L, Rigg A, Hickish T, Archer C, Dent J, Dillon M, Nathan M, Barthelmes L, Rehman S, Sharaiha Y, Innis P, Sai-Giridhar P, Khawaja S. Holt S, et al. Among authors: rigg a. Br J Cancer. 2024 Apr;130(7):1149-1156. doi: 10.1038/s41416-024-02588-9. Epub 2024 Feb 2. Br J Cancer. 2024. PMID: 38308000 Free PMC article.
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Bachelot T, et al. Ann Oncol. 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061. Ann Oncol. 2019. PMID: 30796821 Free article. Clinical Trial.
A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP).
Starkey T, Ionescu MC, Tilby M, Little M, Burke E, Fittall MW, Khan S, Liu JKH, Platt JR, Mew R, Tripathy AR, Watts I, Williams ST, Appanna N, Al-Hajji Y, Barnard M, Benny L, Burnett A, Bytyci J, Cattell EL, Cheng V, Clark JJ, Eastlake L, Gerrand K, Ghafoor Q, Grumett S, Harper-Wynne C, Kahn R, Lee AJX, Lomas O, Lydon A, Mckenzie H; NCRI Consumer Forum; Panneerselvam H, Pascoe JS, Patel G, Patel V, Potter VA, Randle A, Rigg AS, Robinson TM, Roylance R, Roques TW, Rozmanowski S, Roux RL, Shah K, Sheehan R, Sintler M, Swarup S, Taylor H, Tillett T, Tuthill M, Williams S, Ying Y, Beggs A, Iveson T, Lee SM, Middleton G, Middleton M, Protheroe A, Fowler T, Johnson P, Lee LYW. Starkey T, et al. Among authors: rigg as. Sci Rep. 2023 Jul 25;13(1):11327. doi: 10.1038/s41598-023-36990-9. Sci Rep. 2023. PMID: 37491478 Free PMC article.
Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.
Lee LYW, Tilby M, Starkey T, Ionescu MC, Burnett A, Hattersley R, Khan S, Little M, Liu JKH, Platt JR, Tripathy A, Watts I, Williams ST, Appanna N, Al-Hajji Y, Barnard M, Benny L, Buckley A, Cattell E, Cheng V, Clark J, Eastlake L, Gerrand K, Ghafoor Q, Grumett S, Harper-Wynne C, Kahn R, Lee AJX, Lydon A, McKenzie H, Panneerselvam H, Pascoe J, Patel G, Patel V, Potter V, Randle A, Rigg AS, Robinson T, Roylance R, Roques T, Rozmanowski S, Roux RL, Shah K, Sintler M, Taylor H, Tillett T, Tuthill M, Williams S, Beggs A, Iveson T, Lee SM, Middleton G, Middleton M, Protheroe AS, Fittall MW, Fowler T, Johnson P; UK COVID Cancer Programme. Lee LYW, et al. Among authors: rigg as. JAMA Oncol. 2023 Feb 1;9(2):188-196. doi: 10.1001/jamaoncol.2022.5974. JAMA Oncol. 2023. PMID: 36547970 Free PMC article.
Long-term effects of COVID-19 on cancer patients: the experience from Guy's Cancer Centre.
Monroy-Iglesias MJ, Tremble K, Russell B, Moss C, Dolly S, Sita-Lumsden A, Cortellini A, Pinato DJ, Rigg A, Karagiannis SN, Van Hemelrijck M. Monroy-Iglesias MJ, et al. Among authors: rigg a. Future Oncol. 2022 Oct;18(32):3585-3594. doi: 10.2217/fon-2022-0088. Epub 2022 Sep 29. Future Oncol. 2022. PMID: 36172860 Free article.
Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI.
Gupta S, Garcia-Carro C, Prosek JM, Glezerman I, Herrmann SM, Garcia P, Abudayyeh A, Lumlertgul N, Malik AB, Loew S, Beckerman P, Renaghan AD, Carlos CA, Rashidi A, Mithani Z, Deshpande P, Rangarajan S, Shah CV, Seigneux S, Campedel L, Kitchlu A, Shin DS, Coppock G, Ortiz-Melo DI, Sprangers B, Aggarwal V, Benesova K, Wanchoo R, Murakami N, Cortazar FB, Reynolds KL, Sise ME, Soler MJ, Leaf DE; ICPi-AKI Consortium Investigators. Gupta S, et al. J Immunother Cancer. 2022 Sep;10(9):e005646. doi: 10.1136/jitc-2022-005646. J Immunother Cancer. 2022. PMID: 36137651 Free PMC article.
63 results